Federal Contractor Profile
Mesa Biotech INC
$37M obligated·2 awards·1 agencies·2 NAICS
Federal Contracts
Showing contracts 1–7 of 7 total. Sorted by action date, most recent first. Excludes $0 modifications.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Sep 7, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92020C00014 | 334516 | EASY TO USE, LOW-COST MOLECULAR-BASED SARS-COV-2 TEST, HIGHLY SCALABLE RAPID ACCELERATION OF DIAGNOSTICS (RADX) PROGRAM: TECH PROJECT #2244 MESA BIOTECH, INC. | $9.7M |
| May 6, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92020C00014 | 334516 | EASY TO USE, LOW-COST MOLECULAR-BASED SARS-COV-2 TEST, HIGHLY SCALABLE RAPID ACCELERATION OF DIAGNOSTICS (RADX) PROGRAM: TECH PROJECT #2244 MESA BIOTECH, INC. | $9.7M |
| Mar 22, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92020C00014 | 334516 | EASY TO USE, LOW-COST MOLECULAR-BASED SARS-COV-2 TEST, HIGHLY SCALABLE RAPID ACCELERATION OF DIAGNOSTICS (RADX) PROGRAM: TECH PROJECT #2244 MESA BIOTECH, INC. | $295K |
| Nov 5, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50121P00008 | 541715 | ACCULA FLU/SARS-COV-2 INTEGRATED TEST DEVELOPMENT | $13M |
| Sep 4, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92020C00014 | 334516 | EASY TO USE, LOW-COST MOLECULAR-BASED SARS-COV-2 TEST, HIGHLY SCALABLE RAPID ACCELERATION OF DIAGNOSTICS (RADX) PROGRAM: TECH PROJECT #2244 MESA BIOTECH, INC. | $9.1M |
| Aug 11, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92020C00014 | 334516 | EASY TO USE, LOW-COST MOLECULAR-BASED SARS-COV-2 TEST, HIGHLY SCALABLE RAPID ACCELERATION OF DIAGNOSTICS (RADX) PROGRAM: TECH PROJECT #2244 MESA BIOTECH, INC. | $1.0M |
| Jul 30, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92020C00014 | 334516 | EASY TO USE, LOW-COST MOLECULAR-BASED SARS-COV-2 TEST, HIGHLY SCALABLE RAPID ACCELERATION OF DIAGNOSTICS (RADX) PROGRAM: TECH PROJECT #2244 MESA BIOTECH, INC. | $5.0M |
Get Alerted Before Mesa Biotech INC's Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start Free